Group 1 - The company, Zhejiang Zhongxin Fluorine Material Co., Ltd., has recently obtained a "Pesticide Production License" issued by the Zhejiang Provincial Department of Agriculture and Rural Affairs [1] - The license allows the company to commercially produce the pesticide "Avermectin," enhancing its product structure and core competitiveness [1] - The license is valid from January 6, 2026, to January 5, 2031, marking a significant milestone for the company's long-term development [1][4] Group 2 - The acquisition of the pesticide production license is expected to have a positive impact on the company's future operations, although it will not significantly affect the company's performance in the short term [1]

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Group 1 - The company Zhongxin Fluorine Materials (002915) has recently obtained a "Pesticide Production License" issued by the Zhejiang Provincial Department of Agriculture and Rural Affairs [1] - This is the first time the company has acquired a "Pesticide Production License," which provides qualification assurance for the commercial production of its product, oxazolone [1]

Core Viewpoint - Zhongxin Fluorine Materials (002915.SZ) has recently obtained the "Pesticide Production License" issued by the Zhejiang Provincial Department of Agriculture and Rural Affairs, marking the company's first acquisition of such a license, which provides qualification assurance for the commercial production of its product, chlorothalonil [1] Group 1 - The acquisition of the pesticide production license will optimize the company's product structure and positively impact its long-term development [1] - This license enhances the company's core competitiveness [1] - The impact of this license on the company's future production and operations is expected to be positive, although it will not significantly affect the company's performance in the short term [1]

格隆汇1月9日丨中欣氟材(002915.SZ)公布，近日取得了浙江省农业农村厅颁发的《农药生产许可 证》，本次系公司首次取得《农药生产许可证》，为公司噁霉灵产品进行商业化生产提供了资质保障， 有利于优化公司产品结构，对公司长远发展有着积极的推动作用，进一步增强公司的核心竞争力。上述 农药生产许可证的取得对公司未来生产经营将产生积极影响，短期内不会对公司业绩产生重大影响，敬 请投资者注意投资风险。 ...

证券代码：002915 证券简称：中欣氟材 公告编号：2026-001 浙江中欣氟材股份有限公司 关于公司取得《农药生产许可证》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江中欣氟材股份有限公司（以下简称"公司"）于近日取得了浙江省农业 农村厅颁发的《农药生产许可证》，现将相关信息公告如下： 统一社会信用代码：91330600723626031R 法定代表人：徐建国 住所：浙江省绍兴市上虞区杭州湾上虞经济技术开发区经十三路 5 号 生产地址：浙江省绍兴市上虞区杭州湾上虞经济技术开发区经十三路 5 号 生产范围：噁霉灵 首次批准日期：2026 年 01 月 06 日 有效期至：2031 年 01 月 05 日 二、对公司的影响及风险提示 一、《农药生产许可证》的基本信息 编号：农药生许（浙）0103 生产企业名称：浙江中欣氟材股份有限公司 三、备查文件 1、《农药生产许可证》。 特此公告。 浙江中欣氟材股份有限公司董事会 2026 年 1 月 9 日 本次系公司首次取得《农药生产许可证》，为公司噁霉灵产品进行商业化 生产提供了资质保障，有利于优化公 ...

Core Viewpoint - The company has obtained a pesticide production license for the product "Avermectin," which is expected to enhance its competitive edge and optimize product structure, although it will not have a significant short-term impact on performance [1] Group 1 - The company received the pesticide production license from the Zhejiang Provincial Department of Agriculture and Rural Affairs, with the license number being "农药生许（浙）0103" [1] - The production scope of the license includes "Avermectin," with the first approval date set for January 6, 2026, and a validity period until January 5, 2031 [1] - This is the company's first acquisition of such a license, providing qualification assurance for the commercial production of Avermectin [1] Group 2 - The license is expected to positively impact the company's future production and operations by enhancing its core competitiveness [1] - The short-term financial performance is not anticipated to be significantly affected by this development [1]

Group 1: Macro Insights - The bond market's concerns have partially dissipated, with actual impacts being lower than market expectations, but upward policy impulses may continue to pressure market sentiment [2] - The government bond supply's maturity does not strongly explain interest rate trends, and the central bank shows willingness and capability to support liquidity [2] Group 2: Industry Research - Minimax is a leading general multimodal large model platform expected to enter a phase of scaled commercialization by 2025, focusing on self-developed models and an open platform to enhance client engagement [4] - The PEEK industry is poised for growth due to its applications in high-end manufacturing, with significant demand expected in various sectors, including aerospace and medical [7] - The chemical industry is undergoing a supply-side clearing process, with policies aimed at eliminating outdated capacities, which may enhance the competitiveness of leading firms [8] Group 3: Company Research - China Petroleum & Chemical Corporation (Sinopec) is recognized as a high dividend value stock with a robust integrated business model, expected to leverage green transformation for future growth, with projected net profits of 401, 462, and 514 billion yuan for 2025-2027 [9] - Hongrun Construction is anticipated to benefit from collaborations in robotics and new energy projects, with stable fundamentals and growth potential, projecting EPS of 0.23, 0.25, and 0.28 yuan for 2025-2027 [10] - Shuanglin Co., Ltd. is focusing on integrated layouts in the automotive parts sector, with expected net profits of 5.34, 6.47, and 8.11 billion yuan for 2025-2027, highlighting its competitive edge in screw grinding equipment [11]

Core Viewpoint - The price of fluorite in China has increased slightly due to a combination of rising demand from the new energy sector and supply constraints caused by environmental regulations and safety standards [3][4]. Supply and Demand Dynamics - The current price range for fluorite (CaF2≥97%, SiO2≤1.5; wet powder) is between 3260 and 3360 CNY per ton, with an average price of 3310 CNY per ton, reflecting a rise of 10 CNY per ton from the previous day [3][4]. - Demand from the new energy sector, particularly for lithium hexafluorophosphate and PVDF, is expected to increase by approximately 30,000 tons annually, while traditional refrigerant sectors are seeing a mild recovery in export demand [4][7]. - Domestic fluorite mining is constrained by safety and environmental regulations, maintaining an operating rate of 55%-60%, with no new capacity expected [4][5]. Market Conditions - The supply side is experiencing significant contraction due to dual pressures from resource constraints and environmental policies, leading to a decrease in the overall supply of fluorite [5]. - The northern production areas are facing seasonal reductions in output due to harsh weather, while southern production remains stable but insufficient to cover the northern shortfall [5]. - The logistics and trading sectors are affected by low inventory levels and rising transportation costs, which are exacerbated by tightened environmental policies [6]. Purchasing Trends - The market is characterized by resilient demand despite traditional seasonal slowdowns, with stable purchasing from the refrigerant industry and strong support from emerging sectors like new energy and semiconductors [7]. - The long-term demand for high-quality fluorite is being driven by strategic emerging industries, which helps to absorb cost increases from the supply side [7]. Future Outlook - Prices for fluorite are expected to experience a weak recovery, with limited upward potential due to ongoing supply constraints and rising mining costs [8]. - The balance between strong demand from the new energy sector and persistent supply bottlenecks will dictate future price movements, with cautious optimism prevailing in the market [8].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002915 证券简称：中欣氟材 公告编号：2025-089 浙江中欣氟材股份有限公司关于2025年度以简易程序向特定对象发行股票预案及相关文件修订说明的公 告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 浙江中欣氟材股份有限公司（以下简称"公司"）于2025年12月31日召开第七届董事会第五次会议，审议 通过了《关于公司2025年度以简易程序向特定对象发行股票预案（二次修订稿）的议案》等议案，并对 本次以简易程序向特定对象发行股票的相关文件进行了修订。具体情况如下： 根据公司2024年年度股东会的授权，本次发行预案及相关文件的修订无需提交公司股东会审议。本次发 行预案及相关文件主要修订情况如下： ■ 具体内容详见公司同日在《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯网 （http://www.cninfo.com.cn）披露的《浙江中欣氟材股份有限公司2025年度以简易程序向特定对象发行 股票预案（二次修订稿）》《浙江中欣氟材股份有限公司2025年度以简易程序向特定对象发行股票 ...